TY  - JOUR
AU  - Westerman, Mary E.
AU  - Wood, Christopher G.
PY  - 2020
TI  - Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
JF  - Annals of Translational Medicine; Vol 8, No 16 (August 27, 2020): Annals of Translational Medicine
Y2  - 2020
KW  - 
N2  - 
UR  - https://atm.amegroups.org/article/view/39887